Option Care Health (NASDAQ:OPCH) Reaches New 12-Month High – Still a Buy?

Option Care Health, Inc. (NASDAQ:OPCH) shares reached a new 52-week high on Monday . The stock traded as high as $34.49 and last traded at $34.43, with a volume of 489599 shares traded. The stock had previously closed at $33.50.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on OPCH. UBS Group assumed coverage on Option Care Health in a research report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Barrington Research raised their price objective on shares of Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday. The Goldman Sachs Group lowered shares of Option Care Health from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $38.00 to $27.00 in a research report on Monday, November 4th. Finally, Jefferies Financial Group upgraded shares of Option Care Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $26.00 to $35.00 in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.88.

Option Care Health Stock Performance

The stock has a 50 day moving average of $28.70 and a 200 day moving average of $28.06. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The firm has a market cap of $5.78 billion, a price-to-earnings ratio of 28.54, a P/E/G ratio of 2.30 and a beta of 1.35.

Insider Transactions at Option Care Health

In related news, insider Michael Bavaro sold 30,996 shares of Option Care Health stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $33.26, for a total value of $1,030,926.96. Following the transaction, the insider now directly owns 44,974 shares of the company’s stock, valued at $1,495,835.24. The trade was a 40.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Institutional investors have recently made changes to their positions in the stock. Mackenzie Financial Corp raised its position in shares of Option Care Health by 1.1% during the fourth quarter. Mackenzie Financial Corp now owns 49,579 shares of the company’s stock worth $1,150,000 after purchasing an additional 556 shares during the period. Peak Retirement Planning Inc. bought a new stake in Option Care Health during the 4th quarter worth approximately $1,026,000. Public Employees Retirement System of Ohio increased its holdings in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock worth $43,000 after purchasing an additional 332 shares in the last quarter. PharVision Advisers LLC purchased a new stake in shares of Option Care Health in the fourth quarter worth approximately $251,000. Finally, Voloridge Investment Management LLC bought a new position in shares of Option Care Health in the fourth quarter valued at approximately $27,428,000. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.